Edition:
United Kingdom

Checkpoint Therapeutics Inc (CKPT.OQ)

CKPT.OQ on NASDAQ Stock Exchange Capital Market

3.59USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$3.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,992
52-wk High
$10.50
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Checkpoint Therapeutics Reports Q4 Results
Thursday, 15 Mar 2018 

March 15 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.CHECKPOINT THERAPEUTICS INC - ‍AS OF DECEMBER 31, 2017, CHECKPOINT'S CASH AND CASH EQUIVALENTS TOTALED $19.2 MILLION​.  Full Article

Checkpoint Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 8 Mar 2018 

March 8 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING OF 4.60 MILLION COMMON SHARES PRICED AT $4.35PER SHARE.  Full Article

Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Checkpoint Therapeutics Inc :Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Checkpoint Therapeutics receives orphan drug designation for CK-101
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Checkpoint Therapeutics Inc ::Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer.Checkpoint Therapeutics Inc - ‍ck-101 is currently being studied in phase 1 dose-escalation portion of a phase 1/2 clinical study​.  Full Article

BRIEF-Checkpoint Therapeutics Initiates Dose Expansion Trial

* CHECKPOINT THERAPEUTICS INITIATES DOSE EXPANSION PORTION OF PHASE 1 TRIAL OF ANTI-PD-L1 ANTIBODY CK-301 Source text for Eikon: Further company coverage: